Dyspepsia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Dyspepsia Market Outlook

Thelansis’s “Dyspepsia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dyspepsia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Dyspepsia Overview

Dyspepsia, characterized by recurrent or episodic discomfort in the upper gastrointestinal tract related to eating, is associated with symptoms like heartburn, acid reflux, regurgitation, indigestion, bloating, early satiety, or weight loss. There are two primary categories of dyspepsia: functional dyspepsia, characterized by abdominal discomfort after eating, and organic dyspepsia, caused by underlying medical conditions like ulcers, gastritis, or gallbladder disease. Various factors can cause dyspepsia. Functional dyspepsia, or nonulcer dyspepsia, constitutes around 60% of cases. Approximately 15% to 25% of dyspeptic patients have gastroduodenal ulcer disease, which cannot be reliably distinguished from functional dyspepsia based on symptoms alone. Atypical gastroesophageal reflux disease accounts for 5% to 15% of cases, with other common culprits including certain medications (such as NSAIDs, Cox-2 inhibitors, Bisphosphonates, Erythromycin, Tetracyclines, Iron, Potassium supplements, Acarbose, Digitalis, and Theophylline), as well as Helicobacter pylori infection. Dyspepsia manifests through symptoms such as increased burping, excessive fullness or bloating during or after meals, and discomfort or pain in the upper abdomen or chest. Treatment options for dyspepsia typically involve dietary adjustments, H. pylori eradication, acid-reducing medications, and using prokinetic and antiemetic agents in various combinations. If left untreated, dyspepsia can progress to more severe conditions like gastroesophageal reflux disease (GERD), peptic ulcer disease, and gastritis. Long-term complications may include anemia, malnutrition, and a weakened immune system due to inadequate nutrient absorption from food.

• The prevalence of dyspepsia varies, affecting between 25% and 40% of the population, translating to approximately 77.5 million to 124 million people in the United States.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: